- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Entecavir Falls Short of Protecting Hep B-infected Patients from HCC
However, a point to note is that this was a small cohort study without a comparator arm.
Patients taking entecavir for chronic hepatitis B are still at risk for hepatocellular carcinoma (HCC), a recent study suggests.
The findings, published online July 10 in Gut, also show that HCC risk scores based on demographic, clinical, and virologic characteristics are poor predictors, especially in Caucasians.
"This is an important study that shows that entecavir, which is a very strong antiviral agent, can very well suppress the virus, silence the disease, and get the disease in remission," Dr. Harry Janssen, a hepatologist at University of Toronto in Canada and a co-author of the study, told Reuters Health.
"This means you have less inflammation, less fibrosis, and less cirrhosis in these patients, but it does not prevent liver cancer," he said. "It is probably the case that the number of patients with liver cancer is reduced, but if you respond to these treatments, liver cancer is not completely eliminated."
Read the report here: http://bit.ly/1njxu8X
Source: Medscape
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
